[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-361582-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-361582-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-roadmap-to-transform-lung-cancer-outcomes-priorities-in-biology-therapeutic-innovation-early-detection","A Roadmap to Transform Lung Cancer Outcomes - Priorities in Biology, Therapeutic Innovation, Early Detection","","Roadmap-style cancer research paper outlining priorities to transform lung cancer outcomes across biology, therapeutic innovation, and early detection. The manuscript includes formal publication details and licensing under CC BY 4.0 International. It identifies corresponding author information and provides authors’ disclosures covering startup affiliations, equity holdings, consultancy roles, and research funding received from multiple healthcare and biotechnology organizations. These disclosures address potential relationships relevant to the study’s technology and findings.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-roadmap-to-transform-lung-cancer-outcomes-priorities-in-biology-therapeutic-innovation-early-detection/361582/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-roadmap-to-transform-lung-cancer-outcomes-priorities-in-biology-therapeutic-innovation-early-detection/361582.png","ImageObject",300,407,{"name":42,"@type":43},"moss~","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What topics does the roadmap focus on for lung cancer outcomes?","Question",{"text":63,"@type":64},"It addresses priorities spanning lung cancer biology, therapeutic innovation, and early detection.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Under what license is the work published?",{"text":68,"@type":64},"The manuscript is licensed under a CC BY 4.0 International license.",{"name":70,"@type":61,"acceptedAnswer":71},"What kind of information is included in the authors’ disclosures?",{"text":72,"@type":64},"The disclosures list founder and equity relationships, consultancy roles, and research funding or meeting support from multiple organizations.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},361582,1790587164,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":108,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Europe PMC unders uthManuscripts Europe M eC und Author Manuscripts  \nEurope PMC Funders Group  \nAuthor Manuscript  \nCancer Discov. Author manuscript; available in PMC 2026 May 16.  \nPublished in final edited form as:  \nCancer Discov. 2026 June 01; 16(6): 1055–1073. doi:10.1158/2159-8290.CD-25-2318 .  \nThis work is licensed under a CC BY 4.0 International license.  \n*Corresponding Author: Charles Swanton, Francis Crick Institute, 1 Midland Road, London NW1 1AT, United Kingdom.  \n[charles.swanton@crick.ac.uk](charles.swanton@crick.ac.uk).  \nAuthors’ Disclosures  \nM.M. Winslow is a founder of and holds equity in Guide Oncology, Inc. C.D. Berg is Chair of the Independent Data Monitoring Committee for the Grail–NHS Galleri Trial; consults for Mercy BioAnalytics, Inc., Optellum Ltd., and Susan Wojcicki Foundation.  \nJ. Downward has acted as a consultant for AstraZeneca, Jubilant, Theras, Roche, Kestrel, and Vividion and has received research funding from Bristol Myers Squibb, Revolution Medicines, Vividion, AstraZeneca and Novartis. R.S. Herbst has received grants from AstraZeneca, Eli Lilly and Company, Genentech/Roche, and Merck and Company; received consulting fees from AstraZeneca, Bristol-Myers Squibb, Candel Therapeutics Inc., Checkpoint Therapeutics, Cybrexa Therapeutics, Eli Lilly and Company, Genentech, Gilead, I-Mab Biopharma, Johnson and Johnson, Mediflix, NextCure, Neuvogen, Novartis, Pfizer, Regeneron Pharmaceuticals, Roche, and Sanofi; received support for attending meetings from AstraZeneca, Genentech/Roche, and Merck and Company; held stocks in Checkpoint Therapeutics and Immunocore Holdings Limited; participated in advisory boards for AstraZeneca, Candel Therapeutics Inc., Checkpoint Therapeutics, Cybrexa Therapeutics, I-Mab Biopharma, and Novartis; served as a board member (non-executive/ independent) for Immunocore Holdings Limited and Junshi Pharmaceuticals; and occupied leadership/fiduciary roles in the American Association for Cancer Research, International Association for the Study of Lung Cancer, and Southwest Oncology Group. J.V. Heymach serves on the advisory committees of AstraZeneca, Bayer, BioNTech AG, BI, BMS, DAVA Oncology, EMD Serono, Janssen Pharmaceuticals, Jazz Pharmaceuticals, ModeX, Ottimo Pharma, Pfizer, Regeneron Pharmaceuticals; receives research support from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Takeda and Taiho; holds equity in Tenaci-T Therapeutics. N. Kraut reports a full-time employment with Boehringer Ingelheim RCV GmbH & Co KG. M. Merad serves on the scientific advisory board and holds stock from Compugen Inc., Creative Medicine Inc., Asher Bio Inc., Dren Bio Inc., Owkin Inc., OSE Inc., DemBio, Inc., and Larkspur Inc. M. Merad also serves on the scientific advisory board of Genenta Inc.; receives funding for contracted research from Regeneron Inc., Boehringer Ingelheim Inc.; a co-inventor on an issued patent for multiplex immunohistochemistry to characterize tumors and treatment responses. The technology is filed through Icahn School of Medicine at Mount Sinai (ISMMS) and is currently unlicensed. This technology was used to evaluate tissue in this study, and the results could impact the value of this technology. M. Meyerson is a consultant for and holds equity in Bayer, Delve Bio, Isabl, and Karyoverse; receives research funding from Bayer; and is an inventor on licensed patents on lung cancer diagnosis (EGFR mutation) licensed to Labcorp and on lung cancer therapeutics (sevabertinib) licensed to Bayer. T. Pandya has undertaken consultancy work for FutureHouse and Edison Scientific unrelated to the scope of this project; listed on multiple GB patents currently within their priority year on methods for risk prediction of lung cancer.  \nK. Politi acknowledges grants from AstraZeneca, Roche/Genentech, Boehringer Ingelheim, and D2G Oncology; personal fees from AstraZeneca and Revelio Therapeutics, Inc. she is an inventor on a patent related to EGFR T790M mutation testing","cbCaigYEEyFxxBAi","https://ap.wps.com/l/cbCaigYEEyFxxBAi","pdf",2122175,"English","# Publication information and licensing\n## Corresponding author\n## Authors’ disclosures","[{\"question\":\"What topics does the roadmap focus on for lung cancer outcomes?\",\"answer\":\"It addresses priorities spanning lung cancer biology, therapeutic innovation, and early detection.\"},{\"question\":\"Under what license is the work published?\",\"answer\":\"The manuscript is licensed under a CC BY 4.0 International license.\"},{\"question\":\"What kind of information is included in the authors’ disclosures?\",\"answer\":\"The disclosures list founder and equity relationships, consultancy roles, and research funding or meeting support from multiple organizations.\"}]","A Roadmap to Transform Lung Cancer Outcomes - Priorities in Biology, Therapeutic Innovation, Early Detection | PDF",1790144933,101]